Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
Novo Nordisk has entered a multi billion DKK partnership with Vivtex to develop next generation oral biologic medicines for obesity and diabetes.
The partnership focuses on using Vivtex’s proprietary oral drug delivery technologies to expand Novo Nordisk’s oral portfolio beyond injectable treatments.
The company also announced a major investment to expand manufacturing capacity in Ireland for its GLP 1 treatments.
Novo Nordisk, traded as CPSE:NOVO B, is moving to deepen its presence in obesity and diabetes care with a focus on oral treatments, while reinforcing production capacity in Ireland. The stock last closed at DKK 237.9 and has seen a 35.6% decline over the past 30 days and a 61.7% decline over the past year, which frames these announcements against a backdrop of recent market pressure. For investors, these moves come as the company responds to competitive pressures and pricing shifts in the obesity drug market.
The Vivtex partnership and Irish manufacturing build out are intended to broaden delivery options for GLP 1 based therapies and to support higher potential volumes if newer oral products gain traction. How effectively Novo Nordisk executes on oral biologics and scales its Irish facilities may be important for its position in obesity and diabetes, particularly in light of past share price declines and ongoing competition in the sector.
Stay updated on the most important news stories for Novo Nordisk by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Novo Nordisk.
CPSE:NOVO B Earnings & Revenue Growth as at Mar 2026
We’ve flagged 5 risks for Novo Nordisk. See which could impact your investment.
✅ Price vs Analyst Target: At DKK237.9, the share price is about 28% below the DKK331.90 analyst target.
✅ Simply Wall St Valuation: Simply Wall St estimates the shares are trading 67.6% below fair value.
❌ Recent Momentum: The stock has logged a 35.6% decline over the last 30 days.
There is only one way to know the right time to buy, sell or hold Novo Nordisk: head to Simply Wall St’s company report for the latest analysis of Novo Nordisk’s Fair Value.
📊 The Vivtex partnership and Irish expansion deepen Novo Nordisk’s focus on obesity and diabetes, which sit at the core of its investment case.
📊 Keep an eye on uptake of oral GLP 1 products, capital spending in Ireland, and whether earnings continue to support the current P/E of 10.3x.
⚠️ Recent share price volatility and flagged issues like higher debt and dividend coverage mean execution risk around these projects matters.
For the full picture including more risks and rewards, check out the complete Novo Nordisk analysis. Alternatively, you can check out the community page for Novo Nordisk to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include NOVO-B.CO.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com